Methods and systems for inhibiting foreign-body responses in diabetic patients

A method for delivering insulin to a diabetic patient at a single site of infusion over a period of at least four days, the method comprising infusing the insulin at the single site of infusion using a system comprising:

• a medication reservoir comprising an insulin solution;
• a cannula adapted for subcutaneous insertion into a tissue of a diabetic patient at the single site of infusion;
• a fluid conduit in operable contact with the medication reservoir and the cannula and adapted to deliver insulin from the medication reservoir to the single site of infusion;
• heparin that inhibits-inflammation at the single site of infusion so as to inhibit insulin site loss;
• so that insulin is delivered to the diabetic patient;
• and wherein the heparin is administered according to an extended release profile that delivers heparin to the single site of infusion in a manner sufficient to inhibit inflammation at the single site of infusion for at least 6 days.

A system for delivering insulin to a diabetic patient at a single site of infusion over a period of time, the system comprising:

• a medication reservoir comprising an insulin solution;
• a cannula adapted for subcutaneous insertion into a tissue of a diabetic patient at the single site of infusion;
• a fluid conduit in operable contact with the medication reservoir and the cannula and adapted to deliver insulin from the medication reservoir to the single site of infusion;
• and
• a site loss mitigation composition disposed in operable contact with the fluid conduit inflammation at the single site of infusion so as to inhibit insulin site loss;
• and wherein the site loss mitigation composition comprises heparin in an amount sufficient to administer between 0.1 and 80 U/kg/day to the diabetic patient so as to inhibit site loss in the diabetic patient for at least 4 days.